SEARCH

SEARCH BY CITATION

References

  • 1
    Shoda M. Über die Ursodesoxycholsäure aus Bärengallen und ihre physiologische Wirkung. J Biochem 1927; 7: 505 10.
  • 2
    Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994; 29(Suppl. 204): 1 15.
  • 3
    Poupon R & Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther 1995; 66: 1 15.
  • 4
    Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications. Hepatology 1998; 28: 1449 53.
  • 5
    Iwasaki T. Über die Konstitution der Ursodesoxycholsäure. Z Physiol Chem 1936; 244: 181 93.
  • 6
    Sugata F & Shimugu M. Retrospective studies on gallstones disappearance. Jpn J Gastroenterol 1974; 71: 75 80.
  • 7
    Bachrach WH & Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Dig Dis Sci 1982; 24: 737 61.
  • 8
    Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30: 642 9.
  • 9
    Mijayi K, Akiyama T, Ito M, Urakawa T, Shimaji Y. The effect of ursodeoxycholic acid on liver functions in patients with chronic liver disease. A double-blind study in one institution and the study on the effect on hepatic blood flow. Rinsho Kenkyu 1976; 53: 1395 403.
  • 10
    Yamanaka M, Oto M, Obata H, et al. The examination of the therapeutic efficacy of ursodeoxycholic acid on chronic hepatitis. A double-blind study. Shindan Chiryo 1976; 64: 2150 7.
  • 11
    Fisher MM & Paradine ME. Influence of ursodeoxycholic acid on biochemical parameters in cholestatic disease. Gastroenterology 1986; 90: 17251725.
  • 12
    Poupon R, Poupon RE, Calmus Y, Chretien Y, Ballet F, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834 6.
  • 13
    Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial. Gastroentrology 1989; 97: 1268 74.
  • 14
    Radominska A, Treat S, Little J. Bile acid metabolism and the pathophysiology of cholestasis. Semin Liver Dis 1993; 13: 219 34.
  • 15
    Reichen J, Krähenbühl S, Zimmermann H. Impact of cholestasis on hepatic function; retention of cholephiles and their potential targets. In: Gentilini P et al., eds. Cholestasis. Amsterdam: Elsevier Science, 1994: 167–75.
  • 16
    Hay DW & Carey M. Chemical species of lipids in bile. Hepatology 1990; 12: S6 16.
  • 17
    Queneau PE & Montet JC. Hepatoprotection by hydrophilic bile salts. J Hepatol 1994; 21: 260 8.
  • 18
    Beuers U, Kullak-Ublick GA, Paumgartner G. Mechanism of action of ursodeoxycholic acid in cholestatic syndromes. In: Alvaro D, Benedetti A, Strazzabosco M, eds. Vanishing Bile Duct Syndrome. Pathophysiology and Treatment. Dordrecht: Kluwer Academic Publishers, 1997: 230–9.
  • 19
    Greim H, Czygan P, Schaffner F, Popper H. Determination of bile acids in needle biopsies of human liver. Biochem Med 1973; 8: 280 6.
  • 20
    Setchell KDR, Rodrigues CMP, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997; 112: 226 35.
  • 21
    Fromm H. Cholestasis: Pathogenic role and therapeutic action of bile acids. In: Gentilini P, et al., eds. Cholestasis. Amsterdam: Elsevier Science, 1994: 239–43.
  • 22
    Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994; 121: 207 18.
  • 23
    Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR. Tauroursodeoxycholate increases rat liver ursodeoxycholate levels and limits lithocholate formation better than ursodeoxycholate. Gastroenterology 1995; 109: 564 72.
  • 24
    Cirillo NW & Zwas FR. Ursodeoxycholic acid in the treatment of chronic liver disease. Am J Gastroenterol 1994; 89: 1447 52.
  • 25
    Leuschner U. Ursodeoxycholic acid therapy in primary biliary cirrhosis. Scand J Gastroenterol 1994; 29(Suppl. 204): 40 6.
  • 26
    Batta AK, Salen G, Arora R, et al. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989; 10: 414 19.
  • 27
    Batta AK, Arora R, Salen G, Tint GS, Eskreis D, Katz S. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: Effect of ursodeoxycholic acid treatment. J Lipid Res 1989; 30: 1553 62.
  • 28
    Stiehl A, Rudolph G, Raedsch R, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990; 12: 492 7.
  • 29
    Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98: 424 8.
  • 30
    Crosignani A, Podda M, Battezzati PM, et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991; 14: 1000 7.
  • 31
    Poupon RE, Chretien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy. Hepatology 1993; 17: 599 604.
  • 32
    Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759 66.
  • 33
    Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992; 15: 603 8.
  • 34
    Marteau P, Chazouilleres O, Myara A, Jian R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990; 12: 1206 8.
  • 35
    Eusufzai S, Ericsson S, Crederlund T, Einarsson K, Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by SeHCAT test. Gut 1991; 32: 1044 8.
  • 36
    Rudolph G, Endele R, Senn M, Stiehl A. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis. Hepatology 1993; 17: 1028 32.
  • 37
    Mazzella G, Parini P, Bazzoli F, et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993; 38: 896 902.
  • 38
    Holsti P. Cirrhosis of the liver induced in rabbits by gastric instillation of 3-monohydroxycholynic acid. Nature 1960; 186: 250250.
  • 39
    Javitt JB. Cholestasis in rats induced by taurolithocholate. Nature 1966; 210: 1262 3.
  • 40
    Patel T, Roberts LR, Jones BA, Gores GJ. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 1998; 18: 105 14.
  • 41
    Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, Vlahevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterology 1991; 100: 203 11.
  • 42
    Heuman DM, Pandak WM, Hylemon PB, Vlahevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: In vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991; 14: 920 6.
  • 43
    Heuman DM & Bajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994; 106: 1333 41.
  • 44
    Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990; 12: 486 91.
  • 45
    Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104: 1736 44.
  • 46
    Kitani K & Kanai S. Tauroursodeoxycholate prevents taurocholate-induced cholestasis. Life Sci 1982; 30: 515 23.
  • 47
    Schoelmerich J, Baumgartner U, Miyai K, Gerok W. Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver. J Hepatol 1990; 10: 280 3.
  • 48
    Poo JL, Feldmann G, Erlinger S, et al. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 1992; 102: 1752 9.
  • 49
    Neuman MG, Cameron RG, Shear NH, Bellentani S, Tiribelli C. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology 1995; 109: 555 63.
  • 50
    Vendemiale G, Grattagliano I, Signorile A, Altomare E. Ethanol-induced changes of intracellular thiol compartmentation and protein redox status in the rat liver: Effect of tauroursodeoxycholate. J Hepatol 1998; 28: 46 53.
  • 51
    Peterson TC, Slysz G, Isbrucker R. The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. Immunopharmacology 1998; 39: 181 91.
  • 52
    Hillaire S, Boucher E, Calmus Y, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994; 107: 781 8.
  • 53
    Heuman DM, Bajaj R, Lin Q. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: Implications for bile salt toxicity and cytoprotection. J Lipid Res 1996; 37: 562 73.
  • 54
    Oude Elferink RPJ & Groen AK. The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J Hepatol 1995; 23: 617 25.
  • 55
    Oude Elferink RPJ, Tytgat GNJ, Groen AK. The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB J 1997; 11: 19 28.
  • 56
    Puglielli L, Amigo L, Arrese M, et al. Protective role of biliary cholesterol and phospolipid lamellae against bile acid-induced cell damage. Gastroenterology 1994; 107: 244 54.
  • 57
    Benedetti A, Alvaro D, Bassotti C, et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 1997; 26: 9 21.
  • 58
    Van Nieuwkerk CMJ, Oude Elferink RPJ, Groen AK, et al. Effects of ursodeoxycholate and cholate feeding on liver diseases in FVB mice with disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996; 111: 165 71.
  • 59
    De Vree JML, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998; 95: 282 7.
  • 60
    Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25: 519 23.
  • 61
    Que FG & Gores GJ. Cell death by apoptosis: Basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996; 110: 1238 43.
  • 62
    Celli A & Que FG. Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis 1998; 18: 177 85.
  • 63
    Faubion WA & Gores GJ. Death receptors in liver biology and pathobiology. Hepatology 1999; 29: 1 4.
  • 64
    Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103: 137 45.
  • 65
    Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997; 26: 1399 405.
  • 66
    Graham AM, Dollinger MM, Howie SE, Harrison DJ. Bile duct cells in primary biliary cirrhosis are ‘primed’ for apoptosis. Eur J Gastroenterol Hepatol 1998; 10: 553 7.
  • 67
    Benz C, Angermueller S, Toex U, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 1998; 28: 99 106.
  • 68
    Rodrigues CMP, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101: 2790 9.
  • 69
    Lemasters JJ. The mitochondrial permeability transition: From biochemical curiosity to pathophysiological mechanism. Gastroenterology 1998; 115: 783 6.
  • 70
    Lieser MJ, Park J, Natori S, Jones BA, Bronk SF, Gores GJ. Cholestasis confers resistance to the rat liver mitochondrial permeability transition. Gastroenterology 1998; 115: 693 701.
  • 71
    Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997; 25: 1077 84.
  • 72
    Guicciardi ME & Gores GJ. Is ursodeoxycholic acid an antiapoptotic drug? Hepatology 1998; 28: 1721 3.
  • 73
    Calmus Y, Arvieux C, Gane P, et al. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 1992; 102: 1371 7.
  • 74
    Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology 1992; 103: 617 21.
  • 75
    Calmus Y, Guechot J, Podevin P, Bonnefis MT, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6, and tumor necrosis factor-α production by monocytes. Hepatology 1992; 16: 719 23.
  • 76
    Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990; 11: 12 15.
  • 77
    Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol 1991; 86: 1194 9.
  • 78
    Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune response. Hepatology 1992; 16: 358 64.
  • 79
    Bergamini A, Dini L, Baiocchi L, et al. Bile acids with differing hydrophilic–hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells. Hepatology 1997; 25: 927 33.
  • 80
    Tanaka H & Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem Biophys Res Commun 1992; 188: 942 8.
  • 81
    Mitsuyoshi H, Nakashima T, Inaba K, et al. Ursodeoxycholic acid enhances glucocorticoid-induced tyrosine aminotransferase-gene expression in cultured rat hepatocytes. Biochem Biophys Res Commun 1997; 240: 732 6.
  • 82
    Invernizzi P, Salzman AL, Szabo V, Ueta I, O’Connor M, Setchell KD. Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells and in vivo. Am J Physiol 1997; 273: G131 8.
  • 83
    Poupon RE, Balkau B, Eschwege E, Poupon R and the UDCA–PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548 54.
  • 84
    Kisand KE, Karvonen AL, Vuoristo M, et al. Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis. J Mol Med 1996; 74: 269 74.
  • 85
    Kim WR, Poterucha JJ, Jorgensen RA, et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26: 22 6.
  • 86
    Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and negative primary biliary cirrhosis. Hepatology 1997; 25: 1090 5.
  • 87
    Kuerktschiev D, Subat S, Adler D, Schentke KU. Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. J Hepatol 1993; 18: 373 7.
  • 88
    Nishigaki Y, Ohnishi H, Moriwaki H, Muto Y. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig Dis Sci 1996; 41: 1487 93.
  • 89
    Ohiwa T, Katagiri K, Hoshino M, Hayakawa T, Nakai T. Tauroursodeoxycholate and tauro-beta-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content. Hepatology 1993; 17: 470 6.
  • 90
    Deroubaix X, Coche T, Depiereux E, Feytmans E. Saturation of hepatic transport of taurocholate in rats in vivo. Am J Physiol 1991; 260: G189 96.
  • 91
    Häussinger D, Hallbrucker C, Saha N, Lang F, Gerok W. Cell volume and bile acid excretion. Biochem J 1992; 288: 681 9.
  • 92
    Kitani K, Ohta M, Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol 1985; 248: G407 17.
  • 93
    Galan AI, Jimenez R, Munoz ME, Gonzales J. Effect of ursodeoxycholate on maximal biliary secretion of bilirubin in the rat. Biochem Pharmacol 1990; 39: 1175 80.
  • 94
    Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992; 15: 677 84.
  • 95
    Jazrawi RP, De Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid treatment. Gastroenterology 1994; 106: 134 42.
  • 96
    Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995; 23: 283 9.
  • 97
    Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a double blind, placebo-controlled trial. Hepatology 1992; 16: 707 14.
  • 98
    Heathcote EJ, Cauch Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149 56.
  • 99
    Lindor KD, Dickson ER, Balsus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284 90.
  • 100
    Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336: 691 5.
  • 101
    Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjoevall J. Profiles of bile acids and progesterone metabolites in the urine and serum of women with intrahepatic cholestasis of pregnancy. J Hepatol 1997; 27: 346 57.
  • 102
    Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjoevall J. Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. J Hepatol 1997; 27: 1029 40.
  • 103
    Brites D, Rodrigues CMP, Oliveira N, Da Canceicao Cardoso M, Graca LM. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998; 28: 91 8.
  • 104
    Beuers U, Nathanson MH, Boyer JL. Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes. Gastroenterology 1993; 104: 604 12.
  • 105
    Beuers U, Nathanson MH, Isales CM, Boyer JL. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis. J Clin Invest 1993; 92: 2984 93.
  • 106
    Beuers U, Throckmorton DC, Anderson MS, et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996; 110: 1553 63.
  • 107
    Boyer JL & Soroka CJ. Vesicle targeting to the apical domain regulates bile excretory function in isolated rat hepatocyte couplets. Gastroenterology 1995; 109: 1600 11.
  • 108
    Kubitz R, D’Urso D, Kepler D, Häussinger D. Osmodependent dynamic localization of the multidrug resistance protein 2 in the rat hepatocyte canalicular membrane. Gastroenterology 1997; 113: 1438 42.
  • 109
    Häussinger D, Saha N, Hallbrucker C, Lang F, Gerok W. Involvement of microtubules in the swelling-induced stimulation of taurocholate in perfused rat liver. Biochem J 1993; 291: 355 60.
  • 110
    Schliess F, Kurz AK, Vom Dahl S, Häussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 1997; 113: 1306 14.
  • 111
    Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology 1993; 105: 572 8.
  • 112
    Medina JF, Martinez-Anso E, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997; 25: 12 17.
  • 113
    Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217 27.
  • 114
    Dumont M, Erlinger S, Uchman S. Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport. Gastroenterology 1980; 79: 82 9.
  • 115
    Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side chain shortening on the physiological properties of bile acids: Hepatic transport and effect on biliary excretion of 23-norursodeoxycholate in rodents. Gastroenterology 1986; 90: 837 52.
  • 116
    Lake JR, Renner EL, Scharschmidt BF, et al. Inhibition of Na+/H+ exchange in the rat is associated with decreased ursodeoxycholate hypercholeresis, decreased secretion of unconjugated ursodeoxycholate, and increased ursodeoxycholate glucuronidation. Gastroenterology 1988; 95: 454 63.
  • 117
    Gurantz D, Schteingart CD, Hagey LR, Steinbach JH, Grotmol T, Hofmann AF. Hypercholeresis induced by unconjugated bile acid infusion correlates with recovery in bile of unconjugated bile acids. Hepatology 1991; 13: 540 50.
  • 118
    Nakagawa M, Colombo C, Setchell KDR. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after ursodeoxycholic acid administration. Hepatology 1990; 12: 322 34.
  • 119
    Knyrim K, Vakil N, Pfab R, Classen M. The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man. Hepatology 1989; 10: 134 42.
  • 120
    Oda M, Yokomori H, Ishii K, et al. Ursodeoxycholic acid enhances bile canalicular contractions. Hepatology 1990; 12: A999A999(Abstract).
  • 121
    Phillips MJ, Poucell S, Oda M. Biology of disease. Mechanisms of cholestasis. Lab Invest 1986; 54: 593 608.
  • 122
    Shimokura GH, McGill JM, Schlenker T, Fitz JG. Ursodeoxycholate increases cytosolic calcium concentration and activates Cl currents in a biliary cell line. Gastroenterology 1995; 109: 965 72.
  • 123
    Roman R, Schlenker T, Fitz JG. Ursodeoxycholic acid activates Ca2+-dependent Cl currents in a human biliary cell line. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile Acids in Hepatobiliary Diseases. Lancaster: Kluwer Academic Publishers, 1997: 219–23.
  • 124
    Güldütuna S, Leuschner U, Imhof M, et al. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid. Gastroenterology 1992; 30: 49 54.
  • 125
    Osuga T, Tanaka N, Matsuzaki Y, et al. Effect of ursodeoxycholic acid in chronic active hepatitis and primary biliary cirrhosis. Dig Dis Sci 1989; 34: S49 51.
  • 126
    Battezzati PM, Podda M, Bianchi FB, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: Preliminary analysis of a double-blind multicenter trial. J Hepatol 1993; 17: 332 8.
  • 127
    Batts KP, Jorgensen RA, Dickson ER, Lindor KD. Effects of ursodeoxycholic acid on hepatic inflammation and histologic stage in patients with primary biliary cirrhosis. Am J Gastroenterol 1996; 91: 2314 17.
  • 128
    Eriksson LS, Olsson R, Glauman H, et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 1997; 32: 179 86.
  • 129
    Ludwig J, Dickson ER, McDonald, GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Pathol Anat 1978; 379: 103 12.
  • 130
    Poupon RE, Poupon R, Balkau B and the UDCA–PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342 7.
  • 131
    Lindor KD, Thernau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515 18.
  • 132
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884 90.
  • 133
    Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999; 29: 39 43.
  • 134
    Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72: 1137 40.
  • 135
    Huet PM, Huet J, Deslauriers J. Portal hypertension in patients with primary biliary cirrhosis. In: Lindor KD, Heathcote EJ, Poupon R, eds. Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment. Dordrecht: Kluwer Academic Publishers, 1998: 87–91.
  • 136
    Pasha T, Heathcote J, Gabriel S, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999; 29: 21 6.
  • 137
    Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 1998; 28: 296 301.
  • 138
    Poupon RE, Huet PM, Poupon R, Van Bonnand AM, Nhieu JT, Zafani ES and the UDCA–PBC Study Group. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996; 24: 1098 103.
  • 139
    Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996; 25: 49 57.
  • 140
    Lindor KD, Dickson ER, Jorgensen RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. Hepatology 1995; 22: 1158 62.
  • 141
    Gonzalez-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997; 27: 143 9.
  • 142
    Wolfhagen FHJ, Hoogstraten HJF, Buuren HR, et al. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 1998; 29: 736 42.
  • 143
    Chazouilleres O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11: 120 3.
  • 144
    O’Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991; 14: 838 47.
  • 145
    Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20: 57 64.
  • 146
    Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. J Hepatol 1997; 26: 560 6.
  • 147
    Van Hoogstraten HJF, Wolfhagen FHJ, Van De Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple doses. J Hepatol 1998; 29: 417 23.
  • 148
    Palma J, Reyes H, Ribalta J, et al. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology 1992; 15: 1043 7.
  • 149
    Marpeau L, Chazouillieri D, Rhimi Z, Poupon R, Pigne A, Barrat J. Pregnancy-associated idiopathic intrahepatic cholestasis. Hypothesis of physiopathology: a therapeutic case report. Fetal Diagn Ther 1991; 6: 120 5.
  • 150
    Mazella G, Rizzo N, Salzetta A, Iampieri R, Bovicelli L, Roda E. Management of intrahepatic cholestasis in pregnancy. Lancet 1991; 338: 1594 5.
  • 151
    Brites D, Poeiras J, Rodrigues C. Intrahepatic cholestasis of pregnancy. Etiopathogenesis, prognosis and treatment. Acta Med Port 1994; 7: 181 8.
  • 152
    Davies MH, Da Silva Rcma, Jones SR, Weaver JB, Elias E. Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Gut 1995; 37: 580 4.
  • 153
    Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27: 1022 8.
  • 154
    Meng LJ, Reyes H, Axelson M, et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: Effect of ursodeoxycholic acid therapy. Hepatology 1997; 26: 1573 9.
  • 155
    Fried RH, Murakami CS, Fisher LD, Wilsson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116: 624 9.
  • 156
    Wulffrat NM, Haddad E, Benkerrou M, et al. Hepatic GvHD after HLA-haploidentical bone marrow transplantation in children with severe combined immunodeficiency: The effect of ursodeoxycholic acid. Br J Haematol 1997; 96: 776 80.
  • 157
    Essell JH, Schröder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975 81.
  • 158
    Whitington PF. Cholestasis associated with total parenteral nutrition in infants. Hepatology 1985; 5: 693 6.
  • 159
    Lindor KD & Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report. Gastroenterology 1991; 101: 250 3.
  • 160
    Spagnuolo MA, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for the treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996; 111: 716 19.
  • 161
    Kallinowski B, Theilmann L, Zimmermann R, Gams E, Kommerell B, Stiehl A. Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid. Transplantation 1991; 51: 1128 9.
  • 162
    Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997; 42: 1486 8.
  • 163
    Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol 1996; 91: 1626 30.
  • 164
    Moradpour D, Altorfer J, Flury R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20: 1437 41.
  • 165
    Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis—therapeutic implications and long term follow-up. Arch Dis Child 1993; 68: 653 7.
  • 166
    Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990; 31: 918 21.
  • 167
    Colombo C, Crosignani A, Assaisso M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose response study. Hepatology 1992; 16: 924 30.
  • 168
    Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996; 23: 1484 90.
  • 169
    Lindblad A, Glaumann H, Houwen B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998; 27: 166 74.
  • 170
    Van De Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Van Bijleveld CM, Berge Henegouwen GP. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol 1997; 32: 269 373.
  • 171
    Nittono H, Tokita A, Hayashi M, et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. Biomed Pharmacother 1989; 43: 37 41.
  • 172
    Ullrich D, Rating D, Schröter W, Hanefeld F, Bircher J. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet 1987; 2: 13241324.
  • 173
    Balestreri WF, Setchell KD, Ryckman FC and the UDCA Study Group. Bile acid therapy in pedriatic liver disease. In: Paumgartner G, Stiehl A, Gerok W, eds. Bile Acids and the Hepatobiliary System. London: Kluwer Academic Publishers, 1993: 271–82.
  • 174
    Ros E, Navarro S, Bru C, Gilabert R, Bianchi L, Bruguera M. Ursodeoxycholic acid treatment of primary hepatolithiasis in Caroli’s syndrome. Lancet 1993; 342: 404 6.
  • 175
    Maggiore G & De Giacomo C. Efficacy of ursodeoxycholic acid in preventing cholestatic episodes in a patient with benign recurrent intrahepatic cholestasis. Hepatology 1992; 16: 504504.
  • 176
    Persson H, Friman S, Schersten T, Svanvik J, Karlberg I. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet 1990; 336: 52 3.
  • 177
    Friman S, Persson H, Schersten T, Svanik J, Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplant Proc 1992; 24: 389 90.
  • 178
    Pageaux GP, Blanc P, Perrigault PF, et al. Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 1995; 23: 119 22.
  • 179
    Keiding S, Höckerstedt K, Bjoro K, et al. The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. Transplantation 1997; 63: 1591 4.
  • 180
    Barnes D, Talenti D, Cammell G, et al. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology 1997; 26: 853 7.
  • 181
    Fleckenstein JF, Paredes M, Thuluvath PJ. A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection. Liver Transpl Surg 1998; 4: 276 9.
  • 182
    Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322 7.
  • 183
    Angelico M, Gandin C, Pescarmona E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C. A randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90: 263 9.
  • 184
    Bellentani S, Podda M, Tiribelli C, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993; 19: 459 64.
  • 185
    Bonkovsky HL. Therapy of hepatitis C: Other options. Hepatology 1997; 26(Suppl.1): S143 51.
  • 186
    Kiso S, Kawara S, Imai Y, et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high gamma-glutamyltranspeptidase. J Gastroenterol 1996; 31: 75 80.
  • 187
    Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464 7.
  • 188
    Plevris JN, Hayes PC, Bouchier IAD. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991; 3: 653 6.